Global Dengue Testing Market to reach USD 630.28 million by 2027. Global Dengue Testing Market is valued approximately USD 455.77 million in 2020 and is anticipated to grow with a healthy CAGR of 4.74 % over the forecast period 2021-2027.
Dengue is a mosquito-borne viral disease, prevalent in tropical and sub-tropical regions of the world. There are several methods of detecting the DENV virus such as ELISA-Based test and RT-PCR Based Test.
Global Dengue Testing Market is driven by rising dengue cases mainly in tropical and densely populated countries such as India and China. According to WHO, number of dengue cases reported have increased from 2.4 million in 2010 to 5.2 million in 2019. The rising cases also gives rise to an increased demand of dengue testing kits.
The changing climate in colder countries of Europe has also increased the dengue outbreaks. Dengue spreads fastest in warm and wet climate. With global warming, the temperature has been rising around the world giving more space to dengue spreading mosquitoes. With explosive outbreaks in countries which have never experienced dengue before, the demand for dengue testing market has also hiked.
However, efforts of governments around the world towards eliminating dengue can lead to reduced dengue cases and lower demand of dengue testing kits which can impede the growth of the market over forecast period of 2021-27. Nevertheless, with technological advancements in development of testing kits leading to more efficient and economical testing methods, Dengue Testing Market is likely to increase the market growth during the forecast period.

Regional Analysis of Asia Pacific, North America, Europe, Latin America, and Rest of the World, shows that Asia Pacific is the most significant player across the world in terms of market share owing to suitable climate for dengue vector, high exposure to DENV virus and presence of low- and middle-income countries. At the same time, Asia Pacific is also anticipated to exhibit the highest growth rate over the forecast period 2021-2027. Factors such as rising dengue cases, partnerships between key market players, and increasing awareness programs by governments would create lucrative growth prospects for the Dengue Testing Market across Asia Pacific region.

Major market player included in this report are:
Abbott Laboratories
Abnova Corporation
Euroimmun AG (PerkinElmer)
Certest Biotec S.L.
Diasorin
F. Hoffmann-La Roche Ltd.
InBios International, Inc.
NovaTec Immundiagnostica GmbH
OriGene Technologies
Thermo Fisher Scientific Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product Type:
ELISA-based test
RT-PCR based test
Dengue IgG/IgM test
Others
By End User:
Hospitals
Diagnostic Centers
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027

Target Audience of the Global Dengue Testing Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors